Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releases (https://norgine.com/media)

Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i

Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality

Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality

As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe.

The Warnow seems to be flowing uphill on this cold morning, but it is only the wind that pushes the surface in strong gusts against the direction of flow. This part of the Warnow lies in a nature reserve. The reeds along its banks are home to valuable fa

Counter Drone Technology Leader Sentrycs Announces its latest Public Safety Deals including new customers in North America

Sentrycs Concludes a Year of Record Growth with its C-UAS Technology Capable of Addressing the Growing Drone Threat Across Four Continents

Sentrycs, a technology leader in the Counter-Unmanned Aerial Systems (C-UAS) industry, announced today its continued progress globally within the public safety market. The company recently closed agreements with two new law enforcement organizations, including one in North America. These new agreements will deliver core protocol manipulation sensor solutions

Infosys Achieves Binding Corporate Rules Certification from EU Data Protection Authorities

– First India-headquartered company to receive BCR certification
– An accredited data privacy compliance framework for international data transfers from the EU

Infosys (https://www.infosys.com/) (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it has obtained regulatory approvals for its Binding Corporate Rules (BCR) from the Hesse Data Protection Authority, Germany, following concurrence from the EDPB (European Data

Infosys Strengthens Strategic Collaboration with Google Cloud to Boost Enterprise AI Innovation, Establishes Center of Excellence

Leveraging Infosys Topaz and Google Cloud technology, the center of excellence will foster co-innovation to deliver transformative AI-powered solutions

Infosys (https://www.infosys.com/) (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the launch of a Google Cloud center of excellence, powered by Infosys Topaz (https://www.infosys.com/services/data-ai-topaz.html), to foster enterprise AI innovation. The center will serve

Good overall result and revenue growth for the ZEISS Group

Good overall result and revenue growth for the ZEISS Group

ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide.

– Increasingly challenging market environment for the direct-to-market segments
– Strong growth in the Semiconductor Manufacturing Technology segment
– Ou

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst

Infosys Collaborates with RheinEnergie to help Enterprises Drive their Energy Transition and Sustainability Agenda

Leveraging Infosys Cobalt and Infosys Topaz, the collaboration will help enterprises boost energy efficiency by up to 30–40% while meeting decarbonization goals

Infosys (https://www.infosys.com/) (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced its collaboration with RheinEnergie (https://www.rheinenergie.com/de/), a leading German energy service provider, to help enterprises drive their energy transition and susta

Innovation competition of the German government for digital identity wallets enters final round with Lissi GmbH

Innovation competition of the German government for digital identity wallets enters final round with Lissi GmbH

Lissi GmbH has qualified for the final phase of the EUDI-Wallet prototype competition organised by the German Federal Agency for Leap Innovation (SPRIND). The competition promotes innovative solutions for the implementation of the European eIDAS 2.0 regulation.

“We are proud to have once again convinced the jury and to be part of such a prestigious programme. We would like to express our gratitude to the Federal Ministry of the Interior and Community and SPRIND for the professional and t

dpa mourns the death of Anas Alkharboutli

dpa mourns the death of Anas Alkharboutli

Our photographer Anas Alkharboutli, who documented the civil war in Syria in a unique visual language, has been killed in an airstrike near the Syrian city of Hama. Anas was just 32 years old.The hope for a better future lives on in his photography.

Anas Alkharboutli joined dpa as a photographer in the Middle East in 2017. He reported primarily from the Syrian civil war zone. In the past few days, his pictures have been seen around the world, as Anas was reporting on the new flare-up of the ci